Where T-cell lymphoma treatment begins: subtype, initial therapy, and care in China

After receiving a diagnosis of T-cell lymphoma, the first useful question is which disease that name describes. Some entities mainly involve lymph nodes, others begin in the skin, and others affect particular organs or extranodal sites. Their treatment intensity, use of radiotherapy, and transplant decisions can differ substantially. A treatment discussion needs a sufficiently specific pathology diagnosis, information about disease distribution, and an assessment of the person who will receive therapy.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Systemic mature T-cell lymphomas include peripheral T-cell lymphoma not otherwise specified, nodal lymphomas of T-follicular-helper origin, and systemic anaplastic large cell lymphoma. ALK status is relevant within the last category. An older report using the term angioimmunoblastic T-cell lymphoma may be described within a newer T-follicular-helper classification. Ask the pathologist to explain the relationship between the names rather than assuming that a wording change means a new cancer has developed. NCI PDQ: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment
At the end of initial therapy, the team evaluates residual disease, the response achieved, and the next appropriate step. Complete remission is an important finding, but it does not eliminate the need for follow-up. An uncertain area of uptake may require clinical correlation or tissue confirmation before a major treatment change. A single scan measurement should not become a stand-alone instruction to escalate therapy. Cheson et al.: Lugano classification for lymphoma evaluation and response
State the full pathology diagnosis, known stage, treatment completed so far, and the clinical disagreement or unmet need that the receiving service should address. Attach pathology reports, availability of material for review, original imaging, and a dated treatment history. A disease name and a budget alone rarely allow a reliable individual recommendation.

Quick answer

Full guide

Complete the disease name before comparing regimens

Systemic mature T-cell lymphomas include peripheral T-cell lymphoma not otherwise specified, nodal lymphomas of T-follicular-helper origin, and systemic anaplastic large cell lymphoma. ALK status is relevant within the last category. An older report using the term angioimmunoblastic T-cell lymphoma may be described within a newer T-follicular-helper classification. Ask the pathologist to explain the relationship between the names rather than assuming that a wording change means a new cancer has developed. NCI PDQ: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment

Primary cutaneous disease needs a different framework. Early mycosis fungoides may be managed predominantly with treatments directed at the skin, whereas Sézary syndrome involves additional assessment, including blood findings. A rash alone does not distinguish primary skin lymphoma from systemic disease involving skin. Children and adolescents also need age-appropriate specialist protocols. T-lymphoblastic lymphoma should not be treated simply by borrowing a mature peripheral T-cell regimen. NCI PDQ: Mycosis Fungoides and Sézary Syndrome Treatment NCI PDQ: Childhood Non-Hodgkin Lymphoma Treatment

If the report only says that a T-cell process is suspected, ask what information is missing. The problem may be tissue quantity, additional staining, molecular analysis, or the clinical context. Specialist review of adequate material can change the entire treatment pathway. Excision or an incisional biopsy is preferred when feasible, while the team can assess whether core samples are adequate when surgery is unsuitable. A fine needle sample does not always provide enough structure for reliable subclassification. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Patients often want a treatment name before all this work is finished. The team should explain which outstanding result could change the recommendation and how urgently it is needed. That makes the reason for further pathology concrete and allows the patient to distinguish a necessary diagnostic step from an unexplained delay.

Use staging and fitness assessment for different questions

Imaging, examination, blood tests, and marrow assessment help document disease extent before treatment. PET/CT is useful for many FDG-avid lymphomas, but uptake cannot replace tissue diagnosis. The conditions under which a marrow biopsy can be omitted in some other lymphomas should not be automatically transferred to peripheral T-cell disease. Retain the original images and examination dates so that later response assessment has an appropriate baseline. Cheson et al.: Lugano classification for lymphoma evaluation and response d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Advanced stage describes distribution; it does not by itself establish that care can only be directed at symptoms. The purpose of treatment also depends on the entity, risk assessment, and what the patient can tolerate. Previous cardiac disease, liver or kidney problems, infection, daily functioning, and current medicines can affect the plan. Ask whether the present aim is durable remission, disease control before a transplant, or another clearly described benefit.

Rapidly enlarging masses, breathing compromise, or significant organ dysfunction need prompt clinical assessment. Resolving a diagnostic question and managing an urgent problem may need to proceed together. Do not try leftover steroids on your own to see whether a mass shrinks. If steroids or other treatment have already been used, tell the pathology and oncology teams when and how they were taken so the effects on symptoms and specimens can be considered.

Initial therapy is more than a choice between chemotherapy and a targeted drug

CHOP or a CHOP-like combination remains an important initial approach for several nodal mature T-cell subtypes. Whether to add etoposide, modify intensity, or prioritize a clinical trial depends on the actual entity and the patient's capacity to receive it. Another patient's prescription containing an extra medicine does not establish that yours is incomplete. Each component has a proposed benefit and a toxicity burden that should be explained. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

For systemic anaplastic large cell lymphoma, brentuximab vedotin with CHP is an important option. ECHELON-2 compared that approach with CHOP, but its population was dominated by systemic anaplastic large cell lymphoma. Smaller groups with other histologies did not provide equally definitive independent evidence. CD30 testing matters, while CD30 expression alone does not transform every diagnosis into the same treatment decision. Horwitz et al.: ECHELON-2 five-year results

Evidence and regulatory permission must also be considered separately. The FDA approved the relevant initial combination for CD30-expressing PTCL in the United States. China's 2025 National Health Commission drug guidance describes that initial use under its discussion of other FDA-approved indications, with a different domestic indication list. A center in China should verify the current Chinese label, any proposed off-label process, and its actual pharmacy arrangements. The foreign approval does not establish routine local access. FDA: initial approval of brentuximab vedotin plus chemotherapy for untreated CD30-expressing PTCL 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布

Extranodal NK/T-cell lymphoma illustrates why the complete diagnosis changes the plan. Radiotherapy often has a central role in localized disease, and systemic approaches involve appropriate asparaginase-containing, non-anthracycline regimens rather than simply copying CHOP. EBV-related assessment is also relevant. If the report includes NK/T or a nasal-type designation, ask a team experienced in that entity to explain the sequence of systemic and local treatment. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Reaching remission leads to another decision, not the same decision for everyone

At the end of initial therapy, the team evaluates residual disease, the response achieved, and the next appropriate step. Complete remission is an important finding, but it does not eliminate the need for follow-up. An uncertain area of uptake may require clinical correlation or tissue confirmation before a major treatment change. A single scan measurement should not become a stand-alone instruction to escalate therapy. Cheson et al.: Lugano classification for lymphoma evaluation and response

Selected patients discuss autologous stem cell transplantation as consolidation. Their own cells are collected, and later reinfused to support marrow recovery after intensive treatment. The relevance of this strategy depends on the subtype, risk, and response; it is not a universal requirement after every T-cell lymphoma remission. An allogeneic transplant uses a donor and introduces a different balance of immune effects, graft-versus-host disease, and other risks. Hübel et al.: Other B- and T-Aggressive Lymphomas, EBMT Handbook 2024 NCI: Stem Cell Transplants in Cancer Treatment

When maintenance medication is suggested, ask what supports that use. It may be an established indication, an individualized strategy, or an investigational approach. The 2026 JACKPOT26 study explored golidocitinib after a response to first-line therapy in defined phase 2 cohorts. It is a reason for further study and discussion, not independent proof that every patient in remission should receive long-term treatment. An authorization in relapsed disease does not automatically become a maintenance authorization. Wei et al.: JACKPOT26 maintenance study, Blood Cancer Journal 2026

These decisions may require a second discussion after the response results are available. It can still be helpful to raise them earlier, especially when collection, donor work, or travel could take time. Ask which preparations are sensible now and which should wait for evidence that the planned next treatment is appropriate.

If disease control is inadequate, establish the new problem carefully

Progression during treatment and recurrence after a documented remission describe different courses. The specialist needs each previous regimen, its best response, and reasons for interruption. A fresh biopsy may clarify the nature of the current lesion. Some apparent recurrences represent infection, reactive change, or a different cellular disease process, which would require a different approach. The purpose of repeating tissue assessment is to choose the next treatment on a reliable basis. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Further options can include another chemotherapy regimen, a medicine directed at a relevant marker, an epigenetic or signaling-pathway treatment, or a suitable trial. Chinese guidance lists defined relapsed or refractory PTCL uses for medicines including chidamide and golidocitinib. These are distinct products with separate conditions and safety requirements. JACKPOT8 was a single-arm study, so comparing its response figure with an unrelated study cannot establish that one drug is better than every alternative. 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布 Song et al.: JACKPOT8 Part B, phase 2 golidocitinib study

Allogeneic transplantation may be considered for an eligible patient whose disease is controlled. The discussion should weigh potential durable benefit against transplant complications and the patient's current infection, organ, treatment, and donor circumstances. Ask whether the medicine being started is intended to deepen response, bridge to a transplant, or continue disease control without a planned transplant. That purpose helps explain how later decisions will be made.

Supportive care belongs in the first treatment plan

The patient should know the infection assessment, necessary prevention, and fever instructions before the first cycle. Chemotherapy and some other therapies can reduce neutrophils, making infections urgent. Suppressing a fever with medication and waiting without contacting the team can conceal a serious problem. Identify the local emergency service and the information it will need, especially if treatment is being given away from home. NCI: Infection and Neutropenia during Cancer Treatment

Nerve symptoms, mouth pain, difficulty eating, fatigue, and skin problems also need reporting. They can affect subsequent dosing and the ability to complete treatment. Describe when the problem began and what it prevents: walking comfortably, fastening buttons, eating, or sleeping. Those details give the clinician more useful information than a simple statement that the symptoms are tolerable.

A caregiver can help organize appointments and symptom notes without being expected to make treatment decisions. The clinical team should provide a route for questions between visits, including what to do when the patient is too unwell to communicate. Support is most effective when the family understands both its role and the available professional help.

Make a referral to China specific enough to assess

State the full pathology diagnosis, known stage, treatment completed so far, and the clinical disagreement or unmet need that the receiving service should address. Attach pathology reports, availability of material for review, original imaging, and a dated treatment history. A disease name and a budget alone rarely allow a reliable individual recommendation.

When the center proposes a pathway, verify the steps, current medicine-use conditions, admission arrangements, and supporting services before requesting a renminbi estimate for that scope. Pathology review, an initial chemotherapy admission, radiotherapy, and transplantation have different cost structures. Without confirmed quantities and a defined plan, an individualized total should remain open. Arrange local blood monitoring, prescriptions, and emergency care after return with the clinician who will actually provide them.

After the first full discussion, you should be able to identify the subtype, the immediate treatment goal, and the next assessment that could change the plan. Ask the specialist to explain any unclear point using your own pathology and imaging. Those answers provide a sound basis for later choices and help keep a new medicine name or someone else's treatment experience in its proper context.